Please ensure Javascript is enabled for purposes of website accessibility

3 Reasons Behind Amarin's Strong 2015

By George Budwell - Jan 13, 2016 at 12:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After losing half of its value in 2014, Amarin made a strong comeback in 2015. Here's why.

AMRN Chart

What: Shares of the small-cap biopharma Amarin Corp. (AMRN 2.48%) gained nearly 70% in 2015, according to data provided by S&P Capital IQ. The Irish drugmaker's strong rebound from an abysmal 2014 was the result of three positive catalysts unfolding for its prescription fish oil pill Vascepa, indicated for severely high triglyceride levels (≥500 mg/dL), over the course of the year.

Firstly, Vascepa's annual sales are expected to jump by around 45% to $78 million, when the company closes its book for 2015 in the next few months. While that's still nowhere near the blockbuster figures investors were originally hoping for based on the commercial performance of GlaxoSmithKline's competing pill, Lovaza, this improving sales momentum shows that Vascepa is far from a bust. 

Next up, the company was successful in its legal battle against the FDA regarding Vascepa's New Chemical Entity status -- retroactively enacting a five-year period of exclusivity from the time of approval, meaning exclusivity won't end until July 25, 2017.

Last but certainly not least, Amarin won a second critical legal fight against the FDA centering on the company's ability to talk to doctors about unapproved uses of the drug based on the completed clinical studies examining its effectiveness in patients with only moderately high triglyceride levels.

So what: The Street thinks Amarin's expanded ability to promote Vascepa could boost the drug's sales by a healthy 74% in 2016, helping to dramatically lower the company's net loss per share for the year.

Now what: Looking ahead, Amarin's story is squarely focused on the outcome of the ongoing cardiovascular outcomes study called "REDUCE-IT" that's currently on track to wrap up in 2017 and produce top-line results in early 2018. The core issue is that if Vascepa does indeed show a significant cardiovascular benefit via REDUCE-IT, it will have a much better chance at producing blockbuster type sales akin to Lovaza. 

The downside is that Amarin is going to have to raise a good chunk of cash to complete REDUCE-IT, perhaps before the end of 2016. So, with the company's share price below $2, Amarin may have to perform a reverse split to both meet the listing requirements of the Nasdaq and execute a secondary offering large enough to shore up its balance sheet for the long-haul. All told, investors may want to hold off on buying this stock right now. 

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
AMRN
$1.65 (2.48%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.